RBC Bioscience Statistics
Total Valuation
RBC Bioscience has a market cap or net worth of TWD 265.49 million. The enterprise value is 639.06 million.
Important Dates
The next estimated earnings date is Wednesday, April 21, 2027.
| Earnings Date | Apr 21, 2027 |
| Ex-Dividend Date | Sep 2, 2026 |
Share Statistics
RBC Bioscience has 14.27 million shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 14.27M |
| Shares Outstanding | 14.27M |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | -0.41% |
| Owned by Insiders (%) | 29.02% |
| Owned by Institutions (%) | n/a |
| Float | 8.08M |
Valuation Ratios
The trailing PE ratio is 17.43.
| PE Ratio | 17.43 |
| Forward PE | n/a |
| PS Ratio | 1.27 |
| PB Ratio | 1.27 |
| P/TBV Ratio | 1.37 |
| P/FCF Ratio | 6.26 |
| P/OCF Ratio | 6.11 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 17.48, with an EV/FCF ratio of 15.07.
| EV / Earnings | 41.73 |
| EV / Sales | 3.05 |
| EV / EBITDA | 17.48 |
| EV / EBIT | 30.93 |
| EV / FCF | 15.07 |
Financial Position
The company has a current ratio of 0.71, with a Debt / Equity ratio of 1.89.
| Current Ratio | 0.71 |
| Quick Ratio | 0.31 |
| Debt / Equity | 1.89 |
| Debt / EBITDA | 10.81 |
| Debt / FCF | 9.32 |
| Interest Coverage | 2.31 |
Financial Efficiency
Return on equity (ROE) is 6.41% and return on invested capital (ROIC) is 2.72%.
| Return on Equity (ROE) | 6.41% |
| Return on Assets (ROA) | 2.14% |
| Return on Invested Capital (ROIC) | 2.72% |
| Return on Capital Employed (ROCE) | 3.79% |
| Weighted Average Cost of Capital (WACC) | 3.76% |
| Revenue Per Employee | 4.19M |
| Profits Per Employee | 306,260 |
| Employee Count | 50 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, RBC Bioscience has paid 3.96 million in taxes.
| Income Tax | 3.96M |
| Effective Tax Rate | 20.54% |
Stock Price Statistics
The stock price has increased by +9.41% in the last 52 weeks. The beta is 0.44, so RBC Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +9.41% |
| 50-Day Moving Average | 20.92 |
| 200-Day Moving Average | 19.49 |
| Relative Strength Index (RSI) | 26.90 |
| Average Volume (20 Days) | 13,092 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RBC Bioscience had revenue of TWD 209.59 million and earned 15.31 million in profits. Earnings per share was 1.07.
| Revenue | 209.59M |
| Gross Profit | 99.34M |
| Operating Income | 20.66M |
| Pretax Income | 19.27M |
| Net Income | 15.31M |
| EBITDA | 35.34M |
| EBIT | 20.66M |
| Earnings Per Share (EPS) | 1.07 |
Full Income Statement Balance Sheet
The company has 21.67 million in cash and 395.23 million in debt, with a net cash position of -373.57 million or -26.17 per share.
| Cash & Cash Equivalents | 21.67M |
| Total Debt | 395.23M |
| Net Cash | -373.57M |
| Net Cash Per Share | -26.17 |
| Equity (Book Value) | 209.16M |
| Book Value Per Share | 13.07 |
| Working Capital | -46.88M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 43.43 million and capital expenditures -1.04 million, giving a free cash flow of 42.40 million.
| Operating Cash Flow | 43.43M |
| Capital Expenditures | -1.04M |
| Depreciation & Amortization | 14.68M |
| Net Borrowing | -3.94M |
| Free Cash Flow | 42.40M |
| FCF Per Share | 2.97 |
Full Cash Flow Statement Margins
Gross margin is 47.40%, with operating and profit margins of 9.86% and 7.31%.
| Gross Margin | 47.40% |
| Operating Margin | 9.86% |
| Pretax Margin | 9.19% |
| Profit Margin | 7.31% |
| EBITDA Margin | 16.86% |
| EBIT Margin | 9.86% |
| FCF Margin | 20.23% |
Dividends & Yields
This stock pays an annual dividend of 3.53, which amounts to a dividend yield of 19.00%.
| Dividend Per Share | 3.53 |
| Dividend Yield | 19.00% |
| Dividend Growth (YoY) | 1,478.20% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 469.27% |
| FCF Payout Ratio | 159.39% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 19.07% |
| Earnings Yield | 5.74% |
| FCF Yield | 15.97% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Stock Splits
The last stock split was on August 11, 2025. It was a forward split with a ratio of 1.1.
| Last Split Date | Aug 11, 2025 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |